Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Gynecol Oncol. 2017 May 1;146(1):179–186. doi: 10.1016/j.ygyno.2017.04.023

Figure 4.

Figure 4

A) Cytotoxicity induced on HER2 3+ EOC cells (KRCH31), HER2 1+/0 USC cells (ARK-4), and KRCH31/ARK-4 co-cultures with 1μg/ml of SYD985. A significant increase of killing of HER2 1+/0 USC cells was detected when compared to control (p= 0.001) after treatment with SYD985. B) Cytotoxicity induced on HER2 3+ EOC cells (KRCH31), HER2 1+/0 USC cells (ARK-4), and KRCH31/ARK-4 co-cultures with 1μg/ml of SYD995 (T-DM1). No significant increase of killing of HER2 1+/0 USC cells was detected when compared to control (p= 0.29) after treatment with T-DM1. C) Cytotoxicity induced on HER2 3+ EOC cells (KRCH31), HER2 1+/0 USC cells (ARK-4), and KRCH31 /ARK-4 co-cultures with 1μg/ml of SYD989 (isotype control ADC). No significant increase of killing of HER2 1+/0 USC cells was detected when compared to control (p= 0.51) after treatment with isotype control ADC.